SelfDecode
Interpretation-heavy health WGS. SelfDecode is the strongest reporting layer in the category — ACMG SF v3.3, 800+ pharmacogenomic medications, rare-variant screening — all built on a standard 30× short-read genome. Its distinguishing bet is that interpretation is the product, sequencing is a commodity. Buy this if you value the report depth over sequencing-provenance transparency. Interpretation-heavy health WGS — ACMG + AI-driven reports. Our review covers all eight dimensions we test — from coverage depthcoverageHow many times, on average, each base is read. 30× is the consumer standard; 100× is used for hard-to-call variants and some cancer assays; 1× (low-pass) is suitable for genealogy but not for clinical variant calls. to clinical reporting quality — based on kits purchased with reader-supported funds, timed turnarounds across six orders, and an independent check of raw read filesFASTQRaw sequencing read file. The unprocessed output of the sequencer..
- ＋Reports are the most medically structured in the mainstream-health category — ACMG SF v3.3 lands genuinely actionable findings
- ＋800+ medications in the pharmacogenomics panel — widest we've seen at this price
- ＋Same raw data carries every future SelfDecode report; no retest required for new panels
- ＋HSA/FSA-eligible simplifies the purchase
- —Outsourced sequencing through partner labs — the company markets interpretation more than wet-lab quality
- —AI-driven insight framing can blur probability estimates into clinical-looking advice
- —Sequencing provenance is not as transparent as Nucleus' Illumina-named partnership
Pricing & coverage tiers
| Tier | Coverage | Price | Best for |
|---|---|---|---|
| Whole Genome Sequencing 30× | 30× | $399 | Consumer standard |
- ACMG SF v3.3 Clinical Predisposition Report
- Advanced Pharmacogenomics (800+ medications)
- Ultimate Rare Variant Screening
- AI-driven disease-risk + longevity insights
US-based storage; HSA/FSA eligible purchase
The SelfDecode dossier, based on public information.
Template narrative · pending independent testing
SelfDecode sits in the consumer whole genome sequencingWGSWhole Genome Sequencing — reading (nearly) all 3 billion base pairs of your DNA, as opposed to genotyping arrays which sample ~600,000 known positions. market at a price point of $399. Sequencing runs on short-read, 30× clinical-grade, through partner labs. Company's public turnaround claim: 6–10 weeks. This section renders a structured summary from public information until our reader-supported testing cycle publishes.
Raw files — BAMBAMAligned reads mapped to a reference genome. The typical intermediate file., FASTQFASTQRaw sequencing read file. The unprocessed output of the sequencer., VCFVCFVariant Call Format — the compact list of positions where your genome differs from the reference. — are available to customers. Interpretation-heavy health WGS. Our editorial verdict at a glance: Interpretation-heavy health WGS. SelfDecode is the strongest reporting layer in the category — ACMG SF v3.3, 800+ pharmacogenomic medications, rare-variant screening — all built on a standard 30× short-read genome. Its distinguishing bet is that interpretation is the product, sequencing is a commodity. Buy this if you value the report depth over sequencing-provenance transparency.
The documented weak spots are outsourced sequencing through partner labs — the company markets interpretation more than wet-lab quality, and sequencing provenance is not as transparent as nucleus' illumina-named partnership. Neither is necessarily a deal-breaker, but both are worth weighing before you click buy.
Editors can replace this template with a full narrative in the Payload admin: Collections → Companies → SelfDecode → Full review (company detail page).